Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Kidney Transplantation | 168 | 2024 | 603 | 33.850 |
Why?
|
Tissue and Organ Procurement | 74 | 2025 | 288 | 18.550 |
Why?
|
Tissue Donors | 63 | 2025 | 388 | 12.240 |
Why?
|
Waiting Lists | 63 | 2025 | 237 | 11.970 |
Why?
|
Kidney Failure, Chronic | 67 | 2024 | 540 | 10.810 |
Why?
|
Graft Survival | 69 | 2024 | 503 | 8.800 |
Why?
|
Living Donors | 53 | 2024 | 287 | 6.830 |
Why?
|
Organ Transplantation | 19 | 2025 | 218 | 6.350 |
Why?
|
Liver Transplantation | 21 | 2025 | 799 | 5.180 |
Why?
|
Registries | 66 | 2024 | 1873 | 4.830 |
Why?
|
Transplant Recipients | 20 | 2024 | 152 | 4.370 |
Why?
|
Graft Rejection | 36 | 2024 | 557 | 4.230 |
Why?
|
Renal Dialysis | 36 | 2024 | 420 | 3.880 |
Why?
|
Lung Transplantation | 8 | 2024 | 278 | 3.640 |
Why?
|
United States | 125 | 2025 | 13785 | 3.610 |
Why?
|
Renal Insufficiency, Chronic | 33 | 2023 | 562 | 3.440 |
Why?
|
Heart Transplantation | 9 | 2024 | 711 | 3.410 |
Why?
|
Healthcare Disparities | 17 | 2024 | 579 | 3.230 |
Why?
|
Quality Indicators, Health Care | 9 | 2018 | 296 | 2.990 |
Why?
|
Transplants | 10 | 2022 | 35 | 2.870 |
Why?
|
Humans | 341 | 2025 | 128019 | 2.640 |
Why?
|
Kidney | 34 | 2024 | 1306 | 2.530 |
Why?
|
Medicare | 15 | 2024 | 715 | 2.500 |
Why?
|
Middle Aged | 163 | 2024 | 30812 | 2.420 |
Why?
|
Health Services Accessibility | 17 | 2025 | 895 | 2.410 |
Why?
|
Adult | 146 | 2024 | 35176 | 2.170 |
Why?
|
Male | 203 | 2024 | 62757 | 2.110 |
Why?
|
Risk Factors | 78 | 2024 | 9696 | 2.100 |
Why?
|
End Stage Liver Disease | 5 | 2024 | 77 | 2.090 |
Why?
|
Donor Selection | 13 | 2023 | 75 | 2.060 |
Why?
|
Aged | 124 | 2024 | 21892 | 2.020 |
Why?
|
Glomerular Filtration Rate | 32 | 2024 | 682 | 2.000 |
Why?
|
Female | 195 | 2024 | 68016 | 1.860 |
Why?
|
Delayed Graft Function | 9 | 2024 | 30 | 1.830 |
Why?
|
Patient Selection | 9 | 2018 | 658 | 1.820 |
Why?
|
Social Determinants of Health | 5 | 2024 | 220 | 1.800 |
Why?
|
Treatment Outcome | 64 | 2024 | 10110 | 1.780 |
Why?
|
Program Evaluation | 8 | 2021 | 872 | 1.680 |
Why?
|
Retrospective Studies | 79 | 2024 | 14404 | 1.640 |
Why?
|
Time Factors | 49 | 2024 | 6479 | 1.530 |
Why?
|
Heart Failure | 10 | 2024 | 2141 | 1.520 |
Why?
|
Transplantation | 4 | 2023 | 25 | 1.490 |
Why?
|
Travel | 4 | 2020 | 121 | 1.480 |
Why?
|
Proportional Hazards Models | 33 | 2023 | 1194 | 1.450 |
Why?
|
Nephrectomy | 11 | 2021 | 158 | 1.420 |
Why?
|
Body Mass Index | 14 | 2024 | 2260 | 1.400 |
Why?
|
Postoperative Complications | 19 | 2024 | 2456 | 1.390 |
Why?
|
Patient Readmission | 6 | 2023 | 663 | 1.260 |
Why?
|
Prognosis | 30 | 2024 | 3766 | 1.250 |
Why?
|
Kidney Diseases | 11 | 2017 | 370 | 1.220 |
Why?
|
Acute Kidney Injury | 12 | 2023 | 777 | 1.210 |
Why?
|
Follow-Up Studies | 35 | 2024 | 4853 | 1.180 |
Why?
|
Mycophenolic Acid | 9 | 2020 | 89 | 1.180 |
Why?
|
Immunosuppressive Agents | 19 | 2020 | 682 | 1.150 |
Why?
|
Risk Assessment | 29 | 2022 | 3223 | 1.140 |
Why?
|
Social Class | 2 | 2021 | 258 | 1.100 |
Why?
|
Cold Ischemia | 5 | 2024 | 28 | 1.060 |
Why?
|
Organ Preservation | 5 | 2024 | 92 | 1.050 |
Why?
|
Resource Allocation | 2 | 2018 | 39 | 1.040 |
Why?
|
Mortality | 5 | 2019 | 306 | 1.020 |
Why?
|
Hospitals, Low-Volume | 2 | 2017 | 22 | 1.020 |
Why?
|
Hospitals, High-Volume | 2 | 2017 | 39 | 1.010 |
Why?
|
Surgicenters | 2 | 2016 | 6 | 0.970 |
Why?
|
Tacrolimus | 7 | 2013 | 140 | 0.930 |
Why?
|
Tissue and Organ Harvesting | 7 | 2024 | 72 | 0.920 |
Why?
|
Adolescent | 50 | 2024 | 20158 | 0.920 |
Why?
|
Young Adult | 37 | 2021 | 12281 | 0.900 |
Why?
|
Life Expectancy | 2 | 2018 | 60 | 0.880 |
Why?
|
Solitary Kidney | 1 | 2023 | 5 | 0.880 |
Why?
|
Cholangitis, Sclerosing | 1 | 2024 | 70 | 0.880 |
Why?
|
Kaplan-Meier Estimate | 17 | 2021 | 851 | 0.860 |
Why?
|
Hospital Records | 2 | 2013 | 11 | 0.860 |
Why?
|
Health Expenditures | 5 | 2020 | 179 | 0.840 |
Why?
|
Survival Rate | 20 | 2024 | 1870 | 0.830 |
Why?
|
Electronic Health Records | 12 | 2021 | 973 | 0.830 |
Why?
|
Informed Consent | 1 | 2024 | 168 | 0.810 |
Why?
|
Global Health | 2 | 2024 | 327 | 0.810 |
Why?
|
Developing Countries | 1 | 2024 | 285 | 0.810 |
Why?
|
Health Policy | 5 | 2016 | 351 | 0.780 |
Why?
|
Benchmarking | 2 | 2021 | 175 | 0.740 |
Why?
|
Nephrology | 3 | 2021 | 60 | 0.730 |
Why?
|
Cardiovascular Diseases | 6 | 2022 | 1994 | 0.710 |
Why?
|
Quality Improvement | 3 | 2019 | 1093 | 0.710 |
Why?
|
Health Facilities | 3 | 2018 | 79 | 0.710 |
Why?
|
Cadaver | 9 | 2019 | 306 | 0.690 |
Why?
|
Nutrition Surveys | 4 | 2016 | 261 | 0.690 |
Why?
|
Pancreas Transplantation | 9 | 2014 | 74 | 0.680 |
Why?
|
Renal Insufficiency | 5 | 2018 | 148 | 0.680 |
Why?
|
Hospital Mortality | 7 | 2020 | 844 | 0.680 |
Why?
|
Aged, 80 and over | 34 | 2024 | 7029 | 0.680 |
Why?
|
Liver Failure, Acute | 1 | 2020 | 63 | 0.670 |
Why?
|
Cohort Studies | 25 | 2024 | 5378 | 0.650 |
Why?
|
Kidney Calculi | 4 | 2021 | 35 | 0.650 |
Why?
|
Cytomegalovirus Infections | 5 | 2024 | 186 | 0.630 |
Why?
|
Ohio | 13 | 2018 | 153 | 0.630 |
Why?
|
Reoperation | 5 | 2015 | 541 | 0.630 |
Why?
|
Myasthenia Gravis | 3 | 2024 | 21 | 0.620 |
Why?
|
Hospitalization | 11 | 2023 | 2057 | 0.610 |
Why?
|
Isoantibodies | 5 | 2024 | 48 | 0.600 |
Why?
|
Quality Assurance, Health Care | 4 | 2019 | 315 | 0.600 |
Why?
|
Emergency Service, Hospital | 11 | 2022 | 1896 | 0.600 |
Why?
|
Receptors, Interleukin-2 | 2 | 2015 | 65 | 0.590 |
Why?
|
Continuity of Patient Care | 2 | 2024 | 275 | 0.590 |
Why?
|
Cause of Death | 10 | 2021 | 392 | 0.580 |
Why?
|
Residence Characteristics | 2 | 2022 | 324 | 0.580 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2017 | 239 | 0.570 |
Why?
|
BK Virus | 4 | 2014 | 13 | 0.560 |
Why?
|
Decision Making | 3 | 2019 | 846 | 0.550 |
Why?
|
Polyomavirus Infections | 4 | 2014 | 27 | 0.550 |
Why?
|
Tumor Virus Infections | 4 | 2014 | 45 | 0.550 |
Why?
|
Population Health | 1 | 2018 | 45 | 0.550 |
Why?
|
Perfusion | 4 | 2024 | 188 | 0.550 |
Why?
|
Surgical Procedures, Operative | 1 | 2019 | 243 | 0.550 |
Why?
|
Hospitals | 4 | 2020 | 631 | 0.540 |
Why?
|
Incidence | 16 | 2024 | 2614 | 0.530 |
Why?
|
Weight Loss | 4 | 2013 | 725 | 0.530 |
Why?
|
Patient Discharge | 3 | 2022 | 850 | 0.530 |
Why?
|
HLA Antigens | 4 | 2011 | 234 | 0.530 |
Why?
|
Obesity | 6 | 2024 | 2859 | 0.530 |
Why?
|
Cardiomyopathy, Restrictive | 1 | 2016 | 9 | 0.520 |
Why?
|
Delivery of Health Care | 3 | 2015 | 888 | 0.520 |
Why?
|
Medical Staff, Hospital | 2 | 2013 | 77 | 0.510 |
Why?
|
Allografts | 7 | 2021 | 136 | 0.510 |
Why?
|
Bayes Theorem | 2 | 2017 | 369 | 0.510 |
Why?
|
Logistic Models | 14 | 2017 | 1975 | 0.510 |
Why?
|
Prospective Studies | 24 | 2023 | 7035 | 0.510 |
Why?
|
Guideline Adherence | 3 | 2019 | 523 | 0.500 |
Why?
|
Clinical Trials as Topic | 8 | 2023 | 997 | 0.500 |
Why?
|
Referral and Consultation | 3 | 2021 | 724 | 0.490 |
Why?
|
Survivors | 2 | 2018 | 462 | 0.490 |
Why?
|
Models, Biological | 3 | 2017 | 1689 | 0.490 |
Why?
|
Metabolic Syndrome | 6 | 2018 | 338 | 0.480 |
Why?
|
Heart Valve Diseases | 2 | 2016 | 151 | 0.480 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2016 | 131 | 0.470 |
Why?
|
Hospital Costs | 1 | 2015 | 114 | 0.470 |
Why?
|
Documentation | 2 | 2013 | 181 | 0.470 |
Why?
|
Histocompatibility Testing | 3 | 2024 | 120 | 0.460 |
Why?
|
Medicaid | 3 | 2024 | 433 | 0.460 |
Why?
|
Recombinant Fusion Proteins | 2 | 2017 | 634 | 0.460 |
Why?
|
Practice Patterns, Physicians' | 5 | 2019 | 1260 | 0.450 |
Why?
|
Models, Theoretical | 2 | 2023 | 541 | 0.450 |
Why?
|
Comorbidity | 14 | 2023 | 1537 | 0.440 |
Why?
|
Age Factors | 13 | 2021 | 3100 | 0.440 |
Why?
|
Testosterone | 2 | 2014 | 369 | 0.440 |
Why?
|
Death | 3 | 2024 | 121 | 0.430 |
Why?
|
Odds Ratio | 9 | 2019 | 1018 | 0.420 |
Why?
|
Dog Diseases | 2 | 2010 | 52 | 0.420 |
Why?
|
Severity of Illness Index | 12 | 2024 | 2703 | 0.410 |
Why?
|
Methylprednisolone | 1 | 2013 | 82 | 0.410 |
Why?
|
Nephrologists | 2 | 2023 | 12 | 0.410 |
Why?
|
Health Care Rationing | 2 | 2010 | 57 | 0.400 |
Why?
|
Blood Specimen Collection | 3 | 2017 | 33 | 0.400 |
Why?
|
Multivariate Analysis | 14 | 2017 | 1492 | 0.400 |
Why?
|
Quality of Health Care | 6 | 2023 | 605 | 0.400 |
Why?
|
Antilymphocyte Serum | 5 | 2020 | 63 | 0.400 |
Why?
|
Insurance, Health | 5 | 2018 | 267 | 0.400 |
Why?
|
Hemolysis | 4 | 2017 | 199 | 0.400 |
Why?
|
Antigens, CD19 | 1 | 2013 | 113 | 0.400 |
Why?
|
Socioeconomic Factors | 4 | 2024 | 1211 | 0.400 |
Why?
|
Inpatients | 2 | 2015 | 464 | 0.390 |
Why?
|
Patient Participation | 3 | 2015 | 409 | 0.390 |
Why?
|
Intensive Care Units | 3 | 2013 | 734 | 0.390 |
Why?
|
Uric Acid | 5 | 2018 | 160 | 0.390 |
Why?
|
Pulmonary Embolism | 1 | 2014 | 202 | 0.380 |
Why?
|
Brain Ischemia | 3 | 2020 | 305 | 0.380 |
Why?
|
Community Health Services | 1 | 2013 | 226 | 0.370 |
Why?
|
Health Status Indicators | 1 | 2012 | 166 | 0.370 |
Why?
|
Azathioprine | 2 | 2020 | 49 | 0.370 |
Why?
|
Internship and Residency | 3 | 2021 | 1043 | 0.360 |
Why?
|
Histocompatibility | 2 | 2017 | 26 | 0.360 |
Why?
|
Sex Factors | 7 | 2024 | 1942 | 0.360 |
Why?
|
Antibodies, Monoclonal | 3 | 2017 | 1354 | 0.350 |
Why?
|
Cat Diseases | 1 | 2010 | 19 | 0.350 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2019 | 1356 | 0.350 |
Why?
|
Creatinine | 9 | 2023 | 478 | 0.350 |
Why?
|
Policy | 2 | 2023 | 143 | 0.350 |
Why?
|
Blood Pressure Determination | 4 | 2019 | 148 | 0.350 |
Why?
|
Government Regulation | 1 | 2010 | 49 | 0.340 |
Why?
|
Predictive Value of Tests | 9 | 2022 | 1934 | 0.340 |
Why?
|
Adipose Tissue | 1 | 2014 | 589 | 0.340 |
Why?
|
Laparotomy | 1 | 2010 | 106 | 0.340 |
Why?
|
Models, Statistical | 6 | 2022 | 621 | 0.330 |
Why?
|
Stroke | 4 | 2020 | 1063 | 0.330 |
Why?
|
Cross-Sectional Studies | 8 | 2024 | 5034 | 0.330 |
Why?
|
Frailty | 2 | 2023 | 153 | 0.330 |
Why?
|
Intraoperative Complications | 1 | 2010 | 129 | 0.330 |
Why?
|
Motor Activity | 1 | 2014 | 667 | 0.320 |
Why?
|
Enzyme Inhibitors | 2 | 2014 | 809 | 0.320 |
Why?
|
Antibodies | 3 | 2022 | 392 | 0.320 |
Why?
|
Apolipoprotein L1 | 2 | 2021 | 13 | 0.320 |
Why?
|
Transplantation Tolerance | 1 | 2009 | 34 | 0.320 |
Why?
|
Syphilis | 2 | 2022 | 32 | 0.320 |
Why?
|
Lithotripsy | 2 | 2019 | 43 | 0.320 |
Why?
|
Heart Defects, Congenital | 1 | 2016 | 747 | 0.320 |
Why?
|
Machine Learning | 2 | 2025 | 442 | 0.310 |
Why?
|
Calcineurin Inhibitors | 2 | 2008 | 59 | 0.310 |
Why?
|
Steroids | 1 | 2009 | 147 | 0.310 |
Why?
|
Ureter | 2 | 2019 | 35 | 0.310 |
Why?
|
Sirolimus | 6 | 2014 | 189 | 0.310 |
Why?
|
Research | 2 | 2010 | 408 | 0.310 |
Why?
|
Risk | 5 | 2019 | 850 | 0.300 |
Why?
|
Databases, Factual | 10 | 2024 | 1264 | 0.290 |
Why?
|
Kidney Function Tests | 5 | 2024 | 145 | 0.290 |
Why?
|
Lung | 2 | 2022 | 3745 | 0.290 |
Why?
|
Body Weight | 2 | 2009 | 930 | 0.290 |
Why?
|
B-Lymphocytes | 1 | 2013 | 812 | 0.290 |
Why?
|
Hematopoietic Stem Cell Transplantation | 5 | 2017 | 573 | 0.280 |
Why?
|
Overweight | 1 | 2012 | 522 | 0.280 |
Why?
|
Disease Progression | 10 | 2021 | 2598 | 0.270 |
Why?
|
Veterans | 1 | 2018 | 1397 | 0.270 |
Why?
|
Child | 14 | 2024 | 20636 | 0.270 |
Why?
|
Hypertension | 6 | 2017 | 1234 | 0.260 |
Why?
|
Laparoscopy | 1 | 2010 | 450 | 0.260 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2020 | 2428 | 0.260 |
Why?
|
Cardiopulmonary Resuscitation | 2 | 2021 | 224 | 0.250 |
Why?
|
Antibodies, Monoclonal, Humanized | 3 | 2017 | 754 | 0.250 |
Why?
|
Cardiac Surgical Procedures | 3 | 2022 | 493 | 0.250 |
Why?
|
Transplantation, Homologous | 6 | 2018 | 389 | 0.250 |
Why?
|
Certification | 2 | 2017 | 94 | 0.250 |
Why?
|
Emigrants and Immigrants | 1 | 2007 | 122 | 0.240 |
Why?
|
Brain Death | 3 | 2024 | 46 | 0.240 |
Why?
|
Liver Diseases | 2 | 2024 | 285 | 0.240 |
Why?
|
Perioperative Period | 2 | 2016 | 48 | 0.240 |
Why?
|
Sex Distribution | 2 | 2017 | 356 | 0.230 |
Why?
|
Patient Navigation | 2 | 2017 | 79 | 0.230 |
Why?
|
Viremia | 3 | 2014 | 130 | 0.230 |
Why?
|
Quality of Life | 5 | 2022 | 2672 | 0.230 |
Why?
|
Chi-Square Distribution | 7 | 2016 | 511 | 0.230 |
Why?
|
Fructose | 2 | 2018 | 106 | 0.230 |
Why?
|
Kidney Neoplasms | 1 | 2008 | 349 | 0.230 |
Why?
|
Reproducibility of Results | 4 | 2024 | 3009 | 0.230 |
Why?
|
Research Design | 2 | 2017 | 1034 | 0.220 |
Why?
|
Calibration | 1 | 2024 | 135 | 0.220 |
Why?
|
Insurance Coverage | 3 | 2016 | 219 | 0.220 |
Why?
|
Blood Pressure | 4 | 2019 | 1711 | 0.210 |
Why?
|
Costs and Cost Analysis | 4 | 2024 | 200 | 0.210 |
Why?
|
Clinical Decision-Making | 2 | 2017 | 302 | 0.210 |
Why?
|
Ureteroscopy | 2 | 2019 | 16 | 0.210 |
Why?
|
Waist Circumference | 2 | 2014 | 138 | 0.210 |
Why?
|
Child, Preschool | 7 | 2024 | 10378 | 0.200 |
Why?
|
Peripheral Vascular Diseases | 1 | 2023 | 102 | 0.200 |
Why?
|
Ambulatory Care Facilities | 3 | 2017 | 226 | 0.200 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2017 | 1272 | 0.200 |
Why?
|
Chronic Disease | 9 | 2024 | 1690 | 0.200 |
Why?
|
Transplantation Conditioning | 3 | 2009 | 165 | 0.200 |
Why?
|
Pandemics | 2 | 2021 | 1473 | 0.200 |
Why?
|
Chlamydia | 1 | 2022 | 9 | 0.200 |
Why?
|
Hospital Charges | 2 | 2019 | 41 | 0.190 |
Why?
|
Patient Education as Topic | 3 | 2017 | 733 | 0.190 |
Why?
|
Diabetic Nephropathies | 3 | 2017 | 278 | 0.190 |
Why?
|
Data Collection | 1 | 2025 | 645 | 0.190 |
Why?
|
Artificial Intelligence | 1 | 2025 | 244 | 0.190 |
Why?
|
Cytomegalovirus | 4 | 2024 | 152 | 0.190 |
Why?
|
Family | 2 | 2024 | 648 | 0.190 |
Why?
|
Defibrillators, Implantable | 2 | 2015 | 297 | 0.190 |
Why?
|
Urologic Diseases | 2 | 2019 | 38 | 0.190 |
Why?
|
Stomach Diseases | 1 | 2021 | 20 | 0.190 |
Why?
|
Glomerulonephritis, IGA | 1 | 2021 | 10 | 0.190 |
Why?
|
Alemtuzumab | 3 | 2017 | 15 | 0.180 |
Why?
|
Gonorrhea | 1 | 2022 | 57 | 0.180 |
Why?
|
Chlamydia Infections | 1 | 2022 | 73 | 0.180 |
Why?
|
Histamine H2 Antagonists | 1 | 2021 | 28 | 0.180 |
Why?
|
Motivation | 2 | 2016 | 544 | 0.180 |
Why?
|
Genital Neoplasms, Female | 1 | 2022 | 81 | 0.180 |
Why?
|
Practice Guidelines as Topic | 3 | 2019 | 1482 | 0.180 |
Why?
|
Proteinuria | 1 | 2021 | 88 | 0.180 |
Why?
|
Data Interpretation, Statistical | 3 | 2019 | 335 | 0.170 |
Why?
|
Proton Pump Inhibitors | 1 | 2021 | 98 | 0.170 |
Why?
|
Job Satisfaction | 1 | 2022 | 201 | 0.170 |
Why?
|
Podocytes | 1 | 2021 | 51 | 0.170 |
Why?
|
Abdominal Fat | 1 | 2020 | 40 | 0.170 |
Why?
|
Liver | 3 | 2023 | 1826 | 0.170 |
Why?
|
Sexually Transmitted Diseases | 1 | 2022 | 150 | 0.170 |
Why?
|
Nephrolithotomy, Percutaneous | 1 | 2019 | 3 | 0.170 |
Why?
|
Acute Disease | 5 | 2017 | 961 | 0.170 |
Why?
|
Insurance Benefits | 1 | 2019 | 12 | 0.170 |
Why?
|
Ventricular Function, Left | 3 | 2019 | 524 | 0.170 |
Why?
|
Androgen Antagonists | 1 | 2020 | 79 | 0.170 |
Why?
|
Serine Endopeptidases | 1 | 2020 | 116 | 0.170 |
Why?
|
Survival Analysis | 5 | 2010 | 1262 | 0.170 |
Why?
|
Income | 3 | 2023 | 189 | 0.160 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2023 | 281 | 0.160 |
Why?
|
Health Facility Administration | 2 | 2010 | 6 | 0.160 |
Why?
|
Magnesium | 1 | 2020 | 150 | 0.160 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 168 | 0.160 |
Why?
|
Viral Load | 3 | 2016 | 449 | 0.160 |
Why?
|
Ureteral Calculi | 1 | 2019 | 13 | 0.160 |
Why?
|
Triticum | 1 | 2019 | 11 | 0.160 |
Why?
|
Thrombectomy | 1 | 2019 | 59 | 0.160 |
Why?
|
Myocardial Revascularization | 2 | 2016 | 70 | 0.160 |
Why?
|
Biomarkers | 7 | 2020 | 3874 | 0.160 |
Why?
|
Career Choice | 1 | 2021 | 207 | 0.160 |
Why?
|
Decision Trees | 1 | 2019 | 90 | 0.160 |
Why?
|
Patient Admission | 1 | 2020 | 182 | 0.160 |
Why?
|
Thrombolytic Therapy | 1 | 2019 | 131 | 0.150 |
Why?
|
Risk Adjustment | 2 | 2010 | 79 | 0.150 |
Why?
|
Internal Medicine | 1 | 2021 | 246 | 0.150 |
Why?
|
Medical Futility | 1 | 2018 | 24 | 0.150 |
Why?
|
Health Care Costs | 2 | 2020 | 366 | 0.150 |
Why?
|
Propensity Score | 5 | 2020 | 264 | 0.150 |
Why?
|
Adiposity | 2 | 2014 | 504 | 0.150 |
Why?
|
Biopsy | 4 | 2021 | 1077 | 0.150 |
Why?
|
Patient Transfer | 1 | 2020 | 161 | 0.150 |
Why?
|
Immunologic Factors | 1 | 2020 | 227 | 0.150 |
Why?
|
Stroke Volume | 2 | 2019 | 588 | 0.150 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 944 | 0.150 |
Why?
|
Terminology as Topic | 1 | 2019 | 199 | 0.150 |
Why?
|
Killer Cells, Natural | 2 | 2014 | 426 | 0.150 |
Why?
|
Heat-Shock Response | 1 | 2018 | 72 | 0.150 |
Why?
|
Hypotension | 1 | 2019 | 115 | 0.140 |
Why?
|
Gout Suppressants | 1 | 2017 | 17 | 0.140 |
Why?
|
Phlebotomy | 1 | 2017 | 18 | 0.140 |
Why?
|
Employment | 2 | 2016 | 165 | 0.140 |
Why?
|
Hyperuricemia | 1 | 2017 | 44 | 0.140 |
Why?
|
Hypernatremia | 1 | 2017 | 9 | 0.140 |
Why?
|
Diabetes Complications | 3 | 2009 | 223 | 0.140 |
Why?
|
Infant | 6 | 2023 | 8912 | 0.140 |
Why?
|
Heart Valve Prosthesis | 1 | 2019 | 111 | 0.140 |
Why?
|
Vitamin D | 2 | 2011 | 380 | 0.140 |
Why?
|
Health Records, Personal | 1 | 2017 | 26 | 0.140 |
Why?
|
Aftercare | 1 | 2019 | 206 | 0.140 |
Why?
|
Fatigue | 1 | 2019 | 316 | 0.140 |
Why?
|
Cholesterol, HDL | 1 | 2018 | 203 | 0.140 |
Why?
|
Drug Overdose | 1 | 2021 | 319 | 0.140 |
Why?
|
Dendritic Cells | 3 | 2005 | 475 | 0.140 |
Why?
|
Hyponatremia | 1 | 2017 | 40 | 0.140 |
Why?
|
Transcatheter Aortic Valve Replacement | 1 | 2019 | 117 | 0.140 |
Why?
|
Body Image | 1 | 2018 | 84 | 0.140 |
Why?
|
Treponema pallidum | 1 | 2016 | 8 | 0.130 |
Why?
|
Case-Control Studies | 6 | 2022 | 3324 | 0.130 |
Why?
|
Financing, Personal | 1 | 2016 | 26 | 0.130 |
Why?
|
Laboratories, Hospital | 1 | 2016 | 14 | 0.130 |
Why?
|
Analgesics, Opioid | 3 | 2021 | 886 | 0.130 |
Why?
|
Multiple Sclerosis | 1 | 2022 | 435 | 0.130 |
Why?
|
Graft vs Host Disease | 4 | 2008 | 238 | 0.130 |
Why?
|
Patient Preference | 1 | 2018 | 185 | 0.130 |
Why?
|
Parental Leave | 1 | 2016 | 23 | 0.130 |
Why?
|
Aortic Valve Stenosis | 1 | 2019 | 215 | 0.130 |
Why?
|
Surveys and Questionnaires | 7 | 2022 | 5353 | 0.130 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2020 | 311 | 0.130 |
Why?
|
ST Elevation Myocardial Infarction | 1 | 2016 | 52 | 0.130 |
Why?
|
Personal Satisfaction | 1 | 2018 | 198 | 0.130 |
Why?
|
Contrast Media | 1 | 2018 | 387 | 0.120 |
Why?
|
HIV Seropositivity | 1 | 2016 | 119 | 0.120 |
Why?
|
Hospitals, General | 1 | 2015 | 21 | 0.120 |
Why?
|
Hypokalemia | 1 | 2015 | 24 | 0.120 |
Why?
|
Specimen Handling | 1 | 2016 | 163 | 0.120 |
Why?
|
Hyperkalemia | 1 | 2015 | 24 | 0.120 |
Why?
|
Affect | 1 | 2018 | 284 | 0.120 |
Why?
|
Stents | 1 | 2019 | 504 | 0.120 |
Why?
|
Health Plan Implementation | 1 | 2016 | 137 | 0.120 |
Why?
|
Regression Analysis | 3 | 2014 | 978 | 0.120 |
Why?
|
Induction Chemotherapy | 1 | 2015 | 70 | 0.120 |
Why?
|
HIV Infections | 2 | 2022 | 2703 | 0.120 |
Why?
|
Catheters | 1 | 2015 | 66 | 0.120 |
Why?
|
Drug Therapy, Combination | 4 | 2020 | 1012 | 0.120 |
Why?
|
Electric Countershock | 1 | 2015 | 105 | 0.120 |
Why?
|
Fear | 1 | 2018 | 325 | 0.120 |
Why?
|
Palliative Care | 1 | 2021 | 714 | 0.120 |
Why?
|
Myocardial Ischemia | 1 | 2016 | 247 | 0.120 |
Why?
|
Length of Stay | 3 | 2016 | 1114 | 0.120 |
Why?
|
Longitudinal Studies | 3 | 2024 | 2706 | 0.110 |
Why?
|
Reimbursement Mechanisms | 1 | 2015 | 84 | 0.110 |
Why?
|
Equipment Design | 1 | 2016 | 515 | 0.110 |
Why?
|
Algorithms | 3 | 2022 | 1609 | 0.110 |
Why?
|
Coronary Artery Bypass | 1 | 2016 | 222 | 0.110 |
Why?
|
Drug Prescriptions | 1 | 2016 | 245 | 0.110 |
Why?
|
Chelating Agents | 1 | 2014 | 66 | 0.110 |
Why?
|
Cost-Benefit Analysis | 3 | 2016 | 567 | 0.110 |
Why?
|
Intention | 2 | 2015 | 162 | 0.110 |
Why?
|
Hemodialysis, Home | 1 | 2014 | 8 | 0.110 |
Why?
|
Respiratory Function Tests | 1 | 2016 | 580 | 0.110 |
Why?
|
Information Services | 1 | 2014 | 46 | 0.110 |
Why?
|
United States Department of Veterans Affairs | 1 | 2018 | 633 | 0.110 |
Why?
|
Opioid-Related Disorders | 1 | 2021 | 480 | 0.110 |
Why?
|
Patient Acceptance of Health Care | 1 | 2020 | 756 | 0.110 |
Why?
|
Health Status | 3 | 2021 | 747 | 0.110 |
Why?
|
Prevalence | 5 | 2024 | 2541 | 0.110 |
Why?
|
Atrial Fibrillation | 1 | 2018 | 374 | 0.110 |
Why?
|
Vascular Resistance | 1 | 2015 | 366 | 0.110 |
Why?
|
Prosthesis-Related Infections | 1 | 2014 | 73 | 0.110 |
Why?
|
Death, Sudden, Cardiac | 1 | 2015 | 179 | 0.110 |
Why?
|
HLA-C Antigens | 1 | 2014 | 35 | 0.110 |
Why?
|
Selection Bias | 2 | 2010 | 37 | 0.110 |
Why?
|
Primary Prevention | 1 | 2015 | 186 | 0.110 |
Why?
|
Postpartum Period | 1 | 2016 | 331 | 0.110 |
Why?
|
Choice Behavior | 1 | 2015 | 164 | 0.110 |
Why?
|
Phosphates | 1 | 2014 | 169 | 0.110 |
Why?
|
House Calls | 1 | 2014 | 123 | 0.110 |
Why?
|
Florida | 2 | 2011 | 92 | 0.110 |
Why?
|
Pancreatic Diseases | 1 | 2013 | 67 | 0.110 |
Why?
|
Patients | 1 | 2015 | 167 | 0.110 |
Why?
|
Subarachnoid Hemorrhage | 1 | 2013 | 62 | 0.100 |
Why?
|
Receptors, KIR | 1 | 2014 | 96 | 0.100 |
Why?
|
Urologic Surgical Procedures | 1 | 2014 | 107 | 0.100 |
Why?
|
Lung Diseases | 1 | 2019 | 713 | 0.100 |
Why?
|
Polymerase Chain Reaction | 2 | 2013 | 1020 | 0.100 |
Why?
|
Public Health | 1 | 2017 | 478 | 0.100 |
Why?
|
Prostatic Neoplasms | 1 | 2020 | 1011 | 0.100 |
Why?
|
Program Development | 1 | 2015 | 357 | 0.100 |
Why?
|
Hyperparathyroidism | 1 | 2012 | 11 | 0.100 |
Why?
|
Alkaline Phosphatase | 1 | 2013 | 142 | 0.100 |
Why?
|
Arrhythmias, Cardiac | 1 | 2015 | 314 | 0.100 |
Why?
|
Dogs | 2 | 2010 | 368 | 0.100 |
Why?
|
HLA-DQ Antigens | 2 | 2024 | 179 | 0.100 |
Why?
|
Hypoalbuminemia | 1 | 2012 | 30 | 0.100 |
Why?
|
Breast Feeding | 1 | 2016 | 422 | 0.100 |
Why?
|
Triglycerides | 2 | 2012 | 523 | 0.100 |
Why?
|
Peritoneal Dialysis | 1 | 2014 | 95 | 0.100 |
Why?
|
Cardiomyopathies | 1 | 2016 | 335 | 0.100 |
Why?
|
Whole-Body Irradiation | 2 | 2009 | 75 | 0.100 |
Why?
|
Patient Care Team | 1 | 2017 | 597 | 0.100 |
Why?
|
Insulin Resistance | 1 | 2020 | 1164 | 0.100 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2015 | 383 | 0.100 |
Why?
|
Anthropometry | 1 | 2012 | 204 | 0.100 |
Why?
|
Clinical Laboratory Techniques | 1 | 2012 | 92 | 0.090 |
Why?
|
Attitude of Health Personnel | 3 | 2021 | 1088 | 0.090 |
Why?
|
Genetic Variation | 1 | 2017 | 933 | 0.090 |
Why?
|
Quality Control | 2 | 2016 | 156 | 0.090 |
Why?
|
Bicarbonates | 1 | 2011 | 42 | 0.090 |
Why?
|
Skin | 1 | 2016 | 711 | 0.090 |
Why?
|
Herpesviridae Infections | 1 | 2012 | 134 | 0.090 |
Why?
|
Transplantation Immunology | 1 | 2011 | 33 | 0.090 |
Why?
|
Diabetes Mellitus | 3 | 2016 | 994 | 0.090 |
Why?
|
Hypophosphatemia | 1 | 2011 | 17 | 0.090 |
Why?
|
International Classification of Diseases | 2 | 2022 | 122 | 0.090 |
Why?
|
Cyclosporine | 3 | 2011 | 170 | 0.090 |
Why?
|
Hospitals, University | 1 | 2011 | 176 | 0.090 |
Why?
|
Percutaneous Coronary Intervention | 1 | 2016 | 466 | 0.090 |
Why?
|
Inflammation | 2 | 2020 | 2646 | 0.090 |
Why?
|
Polycystic Kidney, Autosomal Dominant | 1 | 2014 | 223 | 0.090 |
Why?
|
Caloric Restriction | 1 | 2012 | 108 | 0.090 |
Why?
|
Blood Grouping and Crossmatching | 1 | 2010 | 14 | 0.090 |
Why?
|
Renin | 1 | 2010 | 31 | 0.090 |
Why?
|
Physical Phenomena | 1 | 2010 | 13 | 0.090 |
Why?
|
Glomerulonephritis | 1 | 2010 | 46 | 0.090 |
Why?
|
Urban Population | 1 | 2013 | 440 | 0.090 |
Why?
|
Virus Activation | 2 | 2013 | 83 | 0.090 |
Why?
|
Cats | 1 | 2010 | 209 | 0.090 |
Why?
|
Mothers | 1 | 2016 | 729 | 0.080 |
Why?
|
Antimetabolites | 1 | 2009 | 22 | 0.080 |
Why?
|
Polycythemia | 1 | 2010 | 20 | 0.080 |
Why?
|
Allopurinol | 1 | 2009 | 60 | 0.080 |
Why?
|
Hemodialysis Units, Hospital | 1 | 2009 | 5 | 0.080 |
Why?
|
National Health Programs | 1 | 2009 | 17 | 0.080 |
Why?
|
Heart Block | 1 | 2009 | 40 | 0.080 |
Why?
|
Myeloablative Agonists | 1 | 2009 | 21 | 0.080 |
Why?
|
Cardiovascular Surgical Procedures | 1 | 2009 | 28 | 0.080 |
Why?
|
Busulfan | 1 | 2009 | 15 | 0.080 |
Why?
|
Organizational Innovation | 1 | 2010 | 138 | 0.080 |
Why?
|
Vidarabine | 1 | 2009 | 30 | 0.080 |
Why?
|
Rural Population | 1 | 2013 | 511 | 0.080 |
Why?
|
Least-Squares Analysis | 1 | 2009 | 72 | 0.080 |
Why?
|
Vitamin D Deficiency | 1 | 2011 | 176 | 0.080 |
Why?
|
ABO Blood-Group System | 1 | 2009 | 39 | 0.080 |
Why?
|
Topography, Medical | 1 | 2009 | 11 | 0.080 |
Why?
|
Health Behavior | 1 | 2015 | 740 | 0.080 |
Why?
|
Salaries and Fringe Benefits | 2 | 2022 | 55 | 0.080 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2009 | 90 | 0.080 |
Why?
|
Energy Intake | 1 | 2012 | 454 | 0.080 |
Why?
|
Herpesvirus 3, Human | 1 | 2012 | 330 | 0.080 |
Why?
|
United Kingdom | 1 | 2009 | 258 | 0.080 |
Why?
|
Pacemaker, Artificial | 1 | 2009 | 109 | 0.080 |
Why?
|
Patient Satisfaction | 2 | 2014 | 624 | 0.080 |
Why?
|
Models, Economic | 1 | 2008 | 53 | 0.070 |
Why?
|
Recurrence | 4 | 2021 | 993 | 0.070 |
Why?
|
Minority Groups | 1 | 2010 | 250 | 0.070 |
Why?
|
Control Groups | 1 | 2007 | 11 | 0.070 |
Why?
|
Respiratory Insufficiency | 1 | 2011 | 311 | 0.070 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2014 | 3625 | 0.070 |
Why?
|
Blood Transfusion | 1 | 2009 | 291 | 0.070 |
Why?
|
Health Care Surveys | 2 | 2021 | 556 | 0.070 |
Why?
|
Combined Modality Therapy | 2 | 2019 | 1199 | 0.070 |
Why?
|
Patient Care | 1 | 2007 | 108 | 0.060 |
Why?
|
Hypercalcemia | 1 | 2006 | 18 | 0.060 |
Why?
|
Infant, Newborn | 2 | 2009 | 5688 | 0.060 |
Why?
|
Accreditation | 1 | 2006 | 79 | 0.060 |
Why?
|
Naphthalenes | 1 | 2006 | 56 | 0.060 |
Why?
|
Transportation | 2 | 2016 | 50 | 0.060 |
Why?
|
Age Distribution | 1 | 2006 | 369 | 0.060 |
Why?
|
Pulsatile Flow | 1 | 2005 | 59 | 0.060 |
Why?
|
Interleukin-12 | 1 | 2005 | 118 | 0.060 |
Why?
|
Biomedical Research | 1 | 2011 | 632 | 0.060 |
Why?
|
Critical Illness | 1 | 2011 | 755 | 0.060 |
Why?
|
T-Lymphocytes | 1 | 2013 | 1921 | 0.060 |
Why?
|
Leukocytes | 1 | 2006 | 303 | 0.060 |
Why?
|
Cryopreservation | 1 | 2005 | 97 | 0.060 |
Why?
|
Antigens | 1 | 2006 | 353 | 0.060 |
Why?
|
Stem Cell Transplantation | 1 | 2005 | 165 | 0.060 |
Why?
|
Withholding Treatment | 1 | 2004 | 70 | 0.060 |
Why?
|
Seroepidemiologic Studies | 1 | 2024 | 155 | 0.060 |
Why?
|
Bacterial Infections | 1 | 2006 | 232 | 0.060 |
Why?
|
Foundations | 1 | 2024 | 24 | 0.060 |
Why?
|
Consensus | 2 | 2018 | 607 | 0.060 |
Why?
|
Immunity, Cellular | 1 | 2005 | 263 | 0.050 |
Why?
|
Transplantation, Heterologous | 1 | 2024 | 187 | 0.050 |
Why?
|
Heterografts | 1 | 2024 | 128 | 0.050 |
Why?
|
Eligibility Determination | 1 | 2024 | 63 | 0.050 |
Why?
|
Immunocompromised Host | 2 | 2020 | 195 | 0.050 |
Why?
|
Leukemia | 1 | 2005 | 228 | 0.050 |
Why?
|
Analysis of Variance | 2 | 2020 | 1266 | 0.050 |
Why?
|
Lithium | 1 | 2023 | 37 | 0.050 |
Why?
|
Arterial Pressure | 2 | 2014 | 116 | 0.050 |
Why?
|
Diet | 1 | 2010 | 1198 | 0.050 |
Why?
|
Shock | 1 | 2024 | 92 | 0.050 |
Why?
|
Urinalysis | 1 | 2023 | 69 | 0.050 |
Why?
|
Hypertension, Pulmonary | 1 | 2014 | 1747 | 0.050 |
Why?
|
Health Equity | 1 | 2024 | 82 | 0.050 |
Why?
|
Antineoplastic Agents | 1 | 2013 | 2041 | 0.050 |
Why?
|
Phosphorus | 2 | 2014 | 93 | 0.050 |
Why?
|
Laboratories | 1 | 2023 | 109 | 0.050 |
Why?
|
Liver Cirrhosis | 1 | 2024 | 279 | 0.050 |
Why?
|
Health Personnel | 1 | 2008 | 645 | 0.050 |
Why?
|
Sodium | 1 | 2022 | 202 | 0.050 |
Why?
|
Relative Value Scales | 1 | 2021 | 5 | 0.050 |
Why?
|
Microscopy | 1 | 2023 | 140 | 0.050 |
Why?
|
Educational Status | 1 | 2024 | 470 | 0.050 |
Why?
|
Area Under Curve | 1 | 2022 | 288 | 0.050 |
Why?
|
Recovery of Function | 2 | 2019 | 630 | 0.050 |
Why?
|
Likelihood Functions | 1 | 2021 | 135 | 0.050 |
Why?
|
Brazil | 1 | 2021 | 154 | 0.050 |
Why?
|
Work-Life Balance | 1 | 2021 | 17 | 0.050 |
Why?
|
Unrelated Donors | 1 | 2021 | 36 | 0.050 |
Why?
|
Alleles | 1 | 2024 | 842 | 0.050 |
Why?
|
HIV | 1 | 2022 | 225 | 0.040 |
Why?
|
Workload | 1 | 2022 | 150 | 0.040 |
Why?
|
Europe | 1 | 2021 | 359 | 0.040 |
Why?
|
Databases as Topic | 3 | 2005 | 59 | 0.040 |
Why?
|
Exercise | 1 | 2012 | 1917 | 0.040 |
Why?
|
Disease-Free Survival | 3 | 2008 | 647 | 0.040 |
Why?
|
Animals | 4 | 2024 | 34487 | 0.040 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2005 | 1185 | 0.040 |
Why?
|
ROC Curve | 1 | 2022 | 500 | 0.040 |
Why?
|
United States Public Health Service | 1 | 2019 | 9 | 0.040 |
Why?
|
International Cooperation | 1 | 2020 | 171 | 0.040 |
Why?
|
Clinical Clerkship | 1 | 2021 | 95 | 0.040 |
Why?
|
Prednisone | 1 | 2020 | 230 | 0.040 |
Why?
|
Probability | 1 | 2020 | 304 | 0.040 |
Why?
|
Endothelial Cells | 1 | 2005 | 700 | 0.040 |
Why?
|
Mentors | 1 | 2021 | 178 | 0.040 |
Why?
|
Computer Simulation | 1 | 2023 | 936 | 0.040 |
Why?
|
Calcium Oxalate | 1 | 2018 | 5 | 0.040 |
Why?
|
Injections, Intra-Arterial | 1 | 2018 | 24 | 0.040 |
Why?
|
Renal Replacement Therapy | 1 | 2019 | 87 | 0.040 |
Why?
|
Observational Studies as Topic | 1 | 2019 | 108 | 0.040 |
Why?
|
Postoperative Period | 1 | 2019 | 322 | 0.040 |
Why?
|
Injections, Intravenous | 1 | 2018 | 197 | 0.040 |
Why?
|
Down-Regulation | 1 | 2020 | 630 | 0.040 |
Why?
|
Pain, Postoperative | 1 | 2020 | 222 | 0.040 |
Why?
|
Terminal Care | 1 | 2021 | 234 | 0.040 |
Why?
|
Linear Models | 1 | 2020 | 816 | 0.040 |
Why?
|
Autografts | 1 | 2017 | 42 | 0.040 |
Why?
|
Joint Commission on Accreditation of Healthcare Organizations | 1 | 2017 | 8 | 0.040 |
Why?
|
Lipids | 2 | 2013 | 619 | 0.040 |
Why?
|
Hematologic Neoplasms | 2 | 2009 | 140 | 0.030 |
Why?
|
Pilot Projects | 2 | 2014 | 1559 | 0.030 |
Why?
|
Fee-for-Service Plans | 1 | 2017 | 88 | 0.030 |
Why?
|
Reference Values | 2 | 2011 | 776 | 0.030 |
Why?
|
Silver Staining | 1 | 2016 | 17 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 2 | 2018 | 2509 | 0.030 |
Why?
|
Societies, Medical | 1 | 2020 | 741 | 0.030 |
Why?
|
Coronary Angiography | 1 | 2018 | 306 | 0.030 |
Why?
|
Calcium | 2 | 2014 | 1182 | 0.030 |
Why?
|
Minnesota | 1 | 2016 | 148 | 0.030 |
Why?
|
Echocardiography | 1 | 2019 | 623 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2016 | 267 | 0.030 |
Why?
|
Genotype | 1 | 2021 | 1828 | 0.030 |
Why?
|
Aortic Valve | 1 | 2019 | 346 | 0.030 |
Why?
|
Protective Factors | 1 | 2016 | 91 | 0.030 |
Why?
|
Rabbits | 1 | 2017 | 761 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2017 | 211 | 0.030 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2015 | 89 | 0.030 |
Why?
|
Potassium | 1 | 2015 | 139 | 0.030 |
Why?
|
Lumbosacral Region | 1 | 2015 | 56 | 0.030 |
Why?
|
Poisson Distribution | 1 | 2014 | 73 | 0.030 |
Why?
|
Ultrasonography, Doppler | 1 | 2015 | 118 | 0.030 |
Why?
|
Equipment Failure | 1 | 2015 | 107 | 0.030 |
Why?
|
Mass Screening | 1 | 2022 | 1145 | 0.030 |
Why?
|
Japan | 1 | 2014 | 96 | 0.030 |
Why?
|
Personnel Selection | 1 | 2015 | 72 | 0.030 |
Why?
|
Drug Utilization Review | 1 | 2014 | 57 | 0.030 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 198 | 0.030 |
Why?
|
Treatment Failure | 2 | 2007 | 338 | 0.030 |
Why?
|
Receptors, Natural Killer Cell | 1 | 2014 | 16 | 0.030 |
Why?
|
Housing | 1 | 2015 | 130 | 0.030 |
Why?
|
Pulmonary Wedge Pressure | 1 | 2014 | 66 | 0.030 |
Why?
|
Cell Count | 2 | 2005 | 310 | 0.030 |
Why?
|
Hypogonadism | 1 | 2014 | 83 | 0.030 |
Why?
|
Skilled Nursing Facilities | 1 | 2015 | 129 | 0.030 |
Why?
|
Antihypertensive Agents | 1 | 2017 | 481 | 0.030 |
Why?
|
Coronary Disease | 1 | 2016 | 384 | 0.030 |
Why?
|
Prosthesis Design | 1 | 2015 | 302 | 0.030 |
Why?
|
Health Services Needs and Demand | 1 | 2015 | 262 | 0.030 |
Why?
|
Glucose Metabolism Disorders | 1 | 2013 | 11 | 0.030 |
Why?
|
Organ Size | 1 | 2014 | 440 | 0.030 |
Why?
|
Fluorescent Antibody Technique, Direct | 1 | 2012 | 9 | 0.030 |
Why?
|
Virus Cultivation | 1 | 2012 | 28 | 0.030 |
Why?
|
Medical Audit | 1 | 2013 | 77 | 0.030 |
Why?
|
Remission Induction | 1 | 2013 | 267 | 0.030 |
Why?
|
Health Literacy | 1 | 2015 | 161 | 0.030 |
Why?
|
Health Services | 1 | 2013 | 97 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2015 | 714 | 0.020 |
Why?
|
Hemoglobins | 1 | 2014 | 336 | 0.020 |
Why?
|
Blood Glucose | 2 | 2013 | 2092 | 0.020 |
Why?
|
Arthritis, Rheumatoid | 1 | 2020 | 1088 | 0.020 |
Why?
|
Flow Cytometry | 2 | 2005 | 1140 | 0.020 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2014 | 380 | 0.020 |
Why?
|
Dyslipidemias | 1 | 2013 | 176 | 0.020 |
Why?
|
Life Style | 1 | 2013 | 459 | 0.020 |
Why?
|
Blood Chemical Analysis | 1 | 2011 | 94 | 0.020 |
Why?
|
Hyperlipidemias | 1 | 2011 | 125 | 0.020 |
Why?
|
Parathyroid Hormone | 1 | 2010 | 106 | 0.020 |
Why?
|
Natriuretic Agents | 1 | 2009 | 2 | 0.020 |
Why?
|
Aneurysm | 1 | 2009 | 29 | 0.020 |
Why?
|
Tracheostomy | 1 | 2011 | 119 | 0.020 |
Why?
|
Fibroblast Growth Factors | 1 | 2010 | 170 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2013 | 600 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 2011 | 264 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2011 | 755 | 0.020 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2009 | 99 | 0.020 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2009 | 81 | 0.020 |
Why?
|
Diethylamines | 1 | 2008 | 2 | 0.020 |
Why?
|
Communication | 1 | 2015 | 838 | 0.020 |
Why?
|
Blood Cells | 1 | 2008 | 38 | 0.020 |
Why?
|
Chromones | 1 | 2008 | 45 | 0.020 |
Why?
|
Seasons | 1 | 2011 | 498 | 0.020 |
Why?
|
Smoking | 1 | 2016 | 1459 | 0.020 |
Why?
|
Lymphocyte Count | 1 | 2008 | 150 | 0.020 |
Why?
|
Fasting | 1 | 2009 | 264 | 0.020 |
Why?
|
Qualitative Research | 1 | 2015 | 1224 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2009 | 253 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2012 | 1813 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2011 | 518 | 0.020 |
Why?
|
Drug Combinations | 1 | 2008 | 323 | 0.020 |
Why?
|
Receptor, Angiotensin, Type 1 | 1 | 2007 | 21 | 0.020 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2007 | 27 | 0.020 |
Why?
|
HLA-DP Antigens | 1 | 2007 | 32 | 0.020 |
Why?
|
HLA-A Antigens | 1 | 2007 | 53 | 0.020 |
Why?
|
Preoperative Care | 1 | 2009 | 335 | 0.020 |
Why?
|
Primary Health Care | 1 | 2017 | 1639 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2011 | 1943 | 0.020 |
Why?
|
Electrocardiography | 1 | 2009 | 607 | 0.020 |
Why?
|
Dietary Supplements | 1 | 2010 | 531 | 0.020 |
Why?
|
Physicians | 1 | 2015 | 858 | 0.020 |
Why?
|
Heart Ventricles | 1 | 2009 | 765 | 0.010 |
Why?
|
Phenotype | 1 | 2013 | 3039 | 0.010 |
Why?
|
Critical Care | 1 | 2009 | 550 | 0.010 |
Why?
|
Matched-Pair Analysis | 1 | 2003 | 40 | 0.010 |
Why?
|
Pregnancy | 1 | 2016 | 6355 | 0.010 |
Why?
|
Wounds and Injuries | 1 | 2010 | 705 | 0.010 |
Why?
|
Neoplasms | 1 | 2018 | 2460 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2007 | 842 | 0.010 |
Why?
|
Immunophenotyping | 1 | 2004 | 309 | 0.010 |
Why?
|
Hepatitis C | 1 | 2005 | 234 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 2005 | 601 | 0.010 |
Why?
|
Stem Cells | 1 | 2005 | 577 | 0.010 |
Why?
|
Insulin | 1 | 2009 | 2316 | 0.010 |
Why?
|